Clinical Trials

The management of Inflammatory Bowel Disease (IBD) is complex and time consuming. While Current Procedural Terminology for MTM services are available they are under-utilized given the time constraints placed on practitioners trying to address multiple health care issues during a single visit. There are companies that specialize in patient pharmacy services to improve health care outcomes. Our aim is to utilize these services in a small number of IBD patients to assess effectiveness of such services within a tertiary care practice.

The purpose of this study is to evaluate the impact of education for proper disposal and rate of utility of disposal bag.

The purpose of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of patients with fibromyalgia in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

The purpose of this research is to investigate whether or not a slow and gradual reduction in the amount of opioid medications will affect patients who take a stable dose of these medications for chronic pain.  Opioids are powerful painkillers, and include medications such as hydrocodone (eg Vicodin or Norco), oxycodone, hydromorphone (Dilaudid), Fentanyl, tramadol (Ultram), and morphine.  Although these medications are important in treating pain related to an injury or after surgery, long-term use of these medications can result in potentially dangerous outcomes.  There is some research to suggest that long-term use of these medications for chronic ...

The purpose of this study is to measure patient out-of-pocket outpatient medication cost for patients without prescription drug insurance coverage after discharging from the hospital. Secondary measures include medication primary adherence (filling prescription within 30 days of discharge date), 30-day readmission rates, and subgroup analysis.

This research is being done to better understand how genetic information related to drug dosing and use can affect medical care of patients.

This study is asking to allow access to stored blood sample in the Mayo Clinic Biobank (IRB#08-007049) so researchers can study DNA to find out if genetic variants that play a role in how the body responds to certain drugs, primarily prescription drugs. In this study, we are interested in genetic variants that may affect whether some people:

• need a lower or higher dose of a drug

• are at an increased risk of side effects to a ...

Due to the ongoing opioid epidemic in the United States, there is increased attention and interest in reducing the use of opioid medication after surgery to minimize the risk of opioid tolerance and addiction, decrease the pool of unused opioids available for misuse, and maximize the use of alternative pain management medications and techniques. The purpose of this study is to implement and assess a standard way of prescribing opioids following percutaneous nephrolithotomy. 

The purpose of this study is to personalize pain medication regimens leveraging sensor-driven, digital ecosystems that can recognize subtle markers of pain and over-medication. Multiple sensors will be used to measure the autonomic features of pain and overdose and thereby build a composite and objective profile to determine pain needs and indicators of safety.

The purpose of the study is to assess patients’ use of opioid and non-opioid pain medication following percutaneous nephrolithotomy, as well as to characterize disposal patterns for unused opioid medication after recovery.

The goal of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

Nonadherence to immunosuppression is associated with an increased risk for organ rejection, allograft vasculopathy, and death (De Geest et al., 2014). Immunosuppression nonadherence has been found to be a factor in up to 90% of late acute rejection events that occur after the first year following transplant, and in 13% to 26% of deaths among heart transplant recipients in single-center research studies (De Geest et al., 2005). A prospective cohort study found that for individuals who were nonadherent after their first year following transplant, the risk of a negative clinical event was doubled (Dobbels et al., 2004). In ...